{
  "event_id": "ea15774acbca",
  "ticker": "ACAD",
  "company_name": "ACADIA Pharmaceuticals",
  "drug_name": "DAYBUE",
  "pdufa_date": "20250805",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:LAVENDER Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.064647",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Rett syndrome in adults and children 2 years and older",
    "source": "websearch:LAVENDER Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.064648",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "trofinetide",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:11:33.226880",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Rare Disease",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.406673",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Phase 3",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:11:33.226880",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:LAVENDER Phase 3",
    "confidence": 0.85,
    "evidence": [
      "LAVENDER Phase 3"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.064633",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "0.018",
    "source": "websearch:LAVENDER Phase 3",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.064640",
    "error": null
  },
  "p_value_numeric": 0.018,
  "effect_size": {
    "status": "found",
    "value": "RSBQ improvement p=0.018, CGI-I significant vs placebo",
    "source": "websearch:LAVENDER Phase 3",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.064643",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome",
    "An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome",
    "A 40-Week, Open-label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome"
  ],
  "nct_ids": [
    "NCT04181723",
    "NCT04988867",
    "NCT04279314"
  ],
  "enrollment": {
    "value": 187,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:38:24.733837",
  "enriched_at": "2026-01-12T08:45:39.775064",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "2835bb4c4a46",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": false
  },
  "mechanism_of_action": "IGF-1 analogue",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -158,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:36.890357",
  "is_single_arm": {
    "value": false,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "interventionModel=PARALLEL",
      "allocation=RANDOMIZED"
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-11T08:28:01.870177",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "trial_region": {
    "value": "us_only",
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "countries=['UNITED STATES']..."
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-11T08:28:01.870199",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:31:44.117664"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:31:44.117672"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-12T08:45:28.613824",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Trofinetide for the Treatment of Rett Syndrome, US Trofinetide - Wikipedia Neuren Pharmaceuticals sa"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-12T08:45:32.652934",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-12T08:45:33.618368",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Daybue (trofinetide) FDA Approval History - Drugs.com Trofinetide for the Treatment of Rett Syndrome"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-12T08:45:34.643005",
    "search_status": "FOUND"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-12T08:45:39.774419",
    "search_status": "CONFIRMED_NONE"
  }
}